Patient centric sampling (PCS) involves sampling with smaller volumes, less intrusive collection, and decreased pain. Additionally, many of these technologies can enable remote sample collection. Patient centric sampling can decrease patient burden and increase trial efficiency with additional sampling time points. This data can be critical to establishing pharmacokinetic-pharmacodynamic relationships in drug development. Although there are many examples of successful implementation in clinical research, widespread PCS adoption has been limited due to risk aversion within the industry, lack of investment and concerns around sample quality. However during the COVID-19 travel restrictions, adoption of new approaches became more mainstream. Several patient-centric sampling approaches were employed for COVID-19 testing including at home testing and drive-through testing sites. There was a clear need to collect samples remotely. This spurred investment in new technology. In clinical research, the industry shifted to mobile phlebotomy and remote sample collection to ensure clinical trials could continue. Within the IQ group, there were several case studies of Sponsors employing patient centric sampling to support clinical trials and enable the development of new COVID-19 therapeutics. This illustrates that these approaches are mature and can be successfully implemented. Clinical researchers should consider when PCS is appropriate to decrease patient burden and to capture critical data points that may not coincide with scheduled clinical site visits.